|
Match
|
Document |
Document Title |
|
|
5688664 |
Thrombin activatable plasminogen analogues
A plasminogen analogue activatable by thrombin to have plasmin activity which contains the cleavage site sequence (SEQ ID NO: 23): ##STR1## where Xaa at position 1 represents P4; Xaa at position 2...
|
|
|
5688503 |
Modification of plasminogen activators
Phosphorylated plasminogen activator, such as phosphorylated pro-urokinase (pro-u-PA), which is substantially free from unphosphorylated plasminogen activator, may be obtained by phosphorylating...
|
|
|
5679344 |
Glucosamine composition and method
A glucosamine-containing composition that includes an anti-inflammatory proteolytic enzyme composition to increase the rapidity of physiological availability of the glucosamine and the method of...
|
|
|
5677162 |
Method for activating prothrombin to thrombin
The present invention provides a method for activating prothrombin to thrombin in a prothrombin complex composition comprising at least prothrombin, Factors V, VII, IX, and X, and phospholipid,...
|
|
|
5674489 |
Method to enhance thrombomodulin APC generation using cationic proteins
A method of inhibiting blood coagulation in a patient is provided. This method involves administering to the patient an effective anticoagulant amount of a cationic protein; wherein the cationic...
|
|
|
5672582 |
Thrombin inhibitors
4-substituted cyclohexylamine derivatives which are thrombin catalytic site inhibitors and which are useful as anticoagulants. These compounds show selectivity for thrombin over other trypsin-like...
|
|
|
5665353 |
Composition containing an analog of haemophilus Hin47 with reduced protease activity
An isolated and purified analog of Haemophilus influenzae Hin47 protein has a decreased protease activity which is less than about 10% of that of natural Hin47 protein and preferably substantially...
|
|
|
5648253 |
Inhibitor-resistant urokinase
Mutants of human urokinase are produced which have an altered amino acid sequence in the domain responsible for binding of plasminogen activator inhibitor(s). One example of an inhibitor resistant...
|
|
|
5645833 |
Inhibitor resistant serine proteases
Serine proteases of the chymotrypsin superfamily are modified so that they exhibit resistance to serine protease inhibitors. If such modified serine proteases have fibrinolytic, thrombolytic,...
|
|
|
5637492 |
Activatable fibrinolytic and anti-thrombotic proteins
Proteinaceous compounds are activatable by enzymes of the clotting cascade to have fibrinolytic or clot formation inhibition activity. For example, a plasminogen analogue is activatable to plasmin...
|
|
|
5637299 |
Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen
This invention provides an improved method for enhancing the activity of thrombolytic agents, including t-PA, scu-PA, tcu-PA, streptokinase, acylated plasminogen-streptokinase activator complex...
|
|
|
5632986 |
Phospholipid-targeted thrombolytic agents
Conjugates with an affinity for phospholipids are disclosed. The conjugates comprise a first compound having affinity for phospholipids, with a binding constant that is not greater than about 10 -7...
|
|
|
5626841 |
Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
A method of adjunctive therapy to inhibit reocclusions in a patient, e.g., after thrombolytic therapy or angioplasty, by administering to the patient a bolus of an amount of purified pro-urokinase...
|
|
|
5620688 |
Methods of inhibiting the activation of Factor XIII
Compositions and methods for inhibiting the activation and/or active state of a precursor protein are provided. Compositions provided can bind to a cleavage site of a precursor protein. Also...
|
|
|
5612029 |
Tissue plasminogen activator glycosylation variants with improved therapeutic properties
The invention concerns tissue plasminogen activator (t-PA) variants which are glycosylated at any of positions 103-105, and are devoid of functional carbohydrate structure at position 117 of...
|
|
|
5609631 |
Fibrin D-domain multimer coated prostheses and methods for their production
Methods for coating a prosthetic surface with anti-thrombogenic, or anti-coagulant, proteins are disclosed. The methods involve contacting a surface of a prosthetic material with a composition...
|
|
|
5603936 |
Process for removing light absorbing compounds from epidermal plant cells
A process is provided for harvesting light absorbing compounds from the epidermal cells of a plant. The plant is subjected to artificial light having wavelengths in the range of 260 to 400 nm. The...
|
|
|
5597800 |
Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia
A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen,...
|
|
|
5595743 |
Preparation of herbal medicines by using a multi-enzyme system, herbal medicines prepared and their uses
This invention relates to a process for preparing a herbal medicine by using a multi-enzyme to hydrolyze raw materials. The multi-enzyme system comprises cellulases, proteases, amylases, lipases...
|
|
|
5595735 |
Hemostatic thrombin paste composition
A hemostatic paste composition comprising a hemostatic effective amount of thrombin in a polyethylene glycol base which is preferably prepared by admixing an aqueous solution of thrombin and...
|
|
|
5591431 |
Enhancement of clot lysis
The invention discloses methods and compositions for increasing clot lysis in the presence of exogenous tissue plasminogen activator.
|
|
|
5589169 |
Method and therapeutic compositions for the prevention of fibrin deposition or adhesions
A method and pharmaceutical composition for the prevention of fibrin deposition or adhesion formation by topical application of a composition to a site of potential fibrin deposition or adhesion...
|
|
|
5580560 |
Modified factor VII/VIIa
This application relates to modified blood coagulation factors, DNA sequences coding for such modified factors and a process for their production.
|
|
|
5580962 |
Parenterally administrable drug having thrombolytic activity and containing protein C
A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against...
|
|
|
5580559 |
Hybrid plasminogen activator
Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA...
|
|
|
5578305 |
Methods and preparations for preventing adhesions to organs and parts of organs
Pharmaceutical composition for prevention of adhesions to body organs or parts of body organs within a body cavity at a site of inflammation is disclosed. The pharmaceutical composition contains...
|
|
|
5569458 |
Nutritional formula
A vitamin and mineral formulation which provides for improved absorption of its nutrients by the addition of digestive enzymes to the formula and including the herb goldenseal to prevent the...
|
|
|
5560910 |
Topical anti-inflammatory composition and method
The present invention comprises compositions and methods that are useful for topically treating inflammation caused by a wide variety of diseases. The compositions comprise an effective amount of a...
|
|
|
5556621 |
Tissue plasminogen activator and method of use
The present invention relates to improved plasminogen activators (improved t-PA) which have a prolonged biological half life, an increased stability to heat and acids and can be expected to be...
|
|
|
5549893 |
Use of protein C in the treatment of purpura fulminans
There is disclosed the use of protein C or activated protein C for preparing a drug useful for the maintenance and improvement of the microcirculation in patients suffering from circulatory...
|
|
|
5549894 |
Disinfecton formulations and methods using D-enantiomeric anti-microbial peptides
A method for disinfecting a contact lens, includes the step of contacting the lens with an effective amount of at least one D-enantiomeric anti-microbial agent for a period of time sufficient to...
|
|
|
5532215 |
Antiviral compositions and method of use
The present invention provides a method for inhibiting viral proliferation by preventing or inhibiting viral replication or killing the viruses on contact. Viral replication is prevented or...
|
|
|
5529788 |
Enzyme containing effervescent cleaning tablet
A water-soluble effervescent cleanser tablet comprising at least one proteolytic enzyme, a surfactant and an effervescing agent for use in ultrasonic cleaning equipment.
|
|
|
5527692 |
Methods for producing thrombin
Methods are disclosed for producing thrombin. The protein is produced from host cells transformed or transfected with DNA construct(s) containing information necessary to direct the expression of...
|
|
|
5520913 |
Tissue plasminogen activator having zymogenic properties
Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of...
|
|
|
5520912 |
Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen,...
|
|
|
5520911 |
Variants of plasminogen activators and processes for their production
A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glycosylation sites in regions that are not glycosylated in the native molecule....
|
|
|
5510330 |
Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
The invention involves thromboembolically effective compositions and therapeutic methods. Thrombolytically active proteins are combined with anticoagulants, as long as the anticoagulant is not...
|
|
|
5504001 |
Hybrid plasminogen activator
Hybrid proteins comprising a cross-linking domain derived from a protein that acts as an acyl-donor substrate for factor XIIIa, a fibrin-binding domain, and a serine protease domain are disclosed....
|
|
|
5503850 |
Method and composition for the treatment of thrombosis in a mammal
A composition comprising a plurality of microcapsules suitable for parenteral injection into a mammal comprising a plasminogen activator-containing core, and a semi-permeable biocompatible layer...
|
|
|
5486471 |
Tissue plasminogen activator analogs having modified growth factor domains
Tissue plasminogen activator analogs containing the growth factor domain of native t-PA, the domain having at least one cysteine residue replaced with another amino acid. The t-PA analogs may...
|
|
|
5478558 |
Method of dissolving venous Thrombi using drug containing activated Protein C
A method of dissolving venous thrombi using a thrombolytic, parenterally administrable drug containing activated protein C is described. The drug can be free of serum amyloid P, thrombin activity,...
|
|
|
5474770 |
Biological support for cell cultures constituted by plasma proteins coagulated by thrombin, its use in the preparation of keratocyte cultures, their recovery and their transport for therapeutic purposes
The present invention relates to a biological support for cell cultures formed by the coagulated mixture of a concentrate of plasma proteins and thrombin. The protein concentrate is obtained by...
|
|
|
5470849 |
γ-turn peptidomimetics as fibrinogen antagonists
This invention relates to a method of inhibiting platelet aggregation, and compounds which are mimics of the peptide sequence Arg-Gly-Asp.
|
|
|
5456909 |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders...
|
|
|
5457090 |
Protease nexin-I variants
One or more amino acid residues within the reactive site region of protease nexin-I are altered in order to create analogs or variants of protease nexin-I. These analogs have substantially...
|
|
|
5439679 |
Peptide plasminogen activators
Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator....
|
|
|
5434073 |
Fibrinolytic and anti-thrombotic cleavable dimers
Relatively inactive fusion proteins are activatable by enzymes of the clotting cascade to have fibrinolytic and/or clot formation inhibition activity. For example, a fusion protein comprising two...
|
|
|
5432062 |
Method of proteolytically cleaving prothrombin to produce thrombin
Prothrombin is cleaved by proteases in the presence of a detergent or certain chaotropic substances to produce thrombin. Under these conditions, controlled and restricted proteolysis occurs such...
|
|
|
5426044 |
Minactivin compositions and antibodies to minactivin
A novel human protein, minactivin, can be produced by recombinant DNA technology, Biologically active native minactivin, peptides derived from minactivin, and their amino acid sequences can also be...
|